{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:03:24Z","timestamp":1792152204415,"version":"4.4.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human serum contains two related isoforms of TRACP: TRACP 5a and TRACP 5b. Serum TRACP 5a protein is increased in about one third of rheumatoid arthritis (RA) sera. This study was undertaken to examine the significance of serum TRACP isoforms 5a and 5b as disease markers of inflammation and bone destruction in RA. One hundred eighteen patients were recruited including 50 with RA (25 with nodules), 26 with osteoarthritis (OA), and 42 with other rheumatic diseases. Twenty-six healthy adults served as controls. Serum TRACP 5a activity, TRACP 5a protein, and TRACP 5b activity were determined by in-house immunoassays. C-reactive protein (CRP) was determined by in-house immunoassay using commercial antibodies and CRP. Other commercial markers included bone-specific alkaline phosphatase (BALP), C-telopeptides of type-I collagen (ICTP), cartilage glycoprotein-39 (YKL-40), and IgM rheumatoid factors (IgM-RF). Mean TRACP 5a protein was significantly elevated only in RA compared with healthy controls and other disease groups. TRACP 5a protein correlated significantly only with IgM-RF in RA. Among RA patients, mean TRACP 5a protein and IgM RF were significantly higher in nodule formers. In contrast, TRACP 5b activity was slightly elevated in RA and correlated with BALP, ICTP, and YKL-40 but not with IgM-RF or CRP. Mean TRACP 5b activity was no different in RA patients with or without nodules. TRACP isoforms could be useful disease markers in RA; TRACP 5a protein may be a measure of systemic inflammatory macrophage burden and disease severity. TRACP 5b activity is a marker for osteoclast number and perhaps local or systemic bone destruction.<\/jats:p>","DOI":"10.1359\/jbmr.080329","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T19:40:56Z","timestamp":1208202056000},"page":"1287-1295","source":"Crossref","is-referenced-by-count":40,"title":["Significance of Serum TRACP in Rheumatoid Arthritis"],"prefix":"10.1093","volume":"23","author":[{"given":"Anthony J","family":"Janckila","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA"},{"name":"U.S. Department of Veterans Affairs Medical Center, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Neustadt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Louisville, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung T","family":"Yam","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Louisville, Louisville, Kentucky, USA"},{"name":"U.S. Department of Veterans Affairs Medical Center, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319504235300_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"2024020319504235300_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.0105-2896.2005.00338.x","article-title":"Rheumatic diseases: The effects of inflammation on bone","volume":"208","author":"Walsh","year":"2005","journal-title":"Immunol Rev"},{"key":"2024020319504235300_bib3","first-page":"2366","article-title":"Therapeutic strategies in rheumatoid arthritis over a 40-year period","volume":"31","author":"Kremers","year":"2004","journal-title":"J Rheumatol"},{"key":"2024020319504235300_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000127824.42507.68","article-title":"Bone loss in inflammatory arthritis: Mechanisms and treatment strategies","volume":"16","author":"Walsh","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"2024020319504235300_bib5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard.62.8.722","article-title":"Extra-articular manifestations in rheumatoid arthritis: Incidence trends and risk factors over 46 years","volume":"62","author":"Turesson","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"2024020319504235300_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/oxfordjournals.rheumatology.a031490","article-title":"Prognostic factors in early rheumatoid arthritis","volume":"39","author":"Scott","year":"2000","journal-title":"Rheumatol"},{"key":"2024020319504235300_bib7","doi-asserted-by":"crossref","first-page":"R784","DOI":"10.1186\/ar1733","article-title":"Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin","volume":"7","author":"Raza","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2024020319504235300_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200405000-00013","article-title":"Rheumatoid factor revisited","volume":"16","author":"D\u00f6rner","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"2024020319504235300_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/ard.2006.051391","article-title":"Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review","volume":"65","author":"Avouac","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024020319504235300_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/1529-0131(200201)46:1<21::AID-ART10061>3.0.CO;2-Q","article-title":"Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2024020319504235300_bib11","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/art.22923","article-title":"Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers","volume":"56","author":"Young-Min","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024020319504235300_bib12","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/ar760","article-title":"Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept","volume":"5","author":"Crnkic","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"2024020319504235300_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/ard.59.7.544","article-title":"Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions","volume":"59","author":"Vos","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2024020319504235300_bib14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1515\/CCLM.2003.160","article-title":"Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis","volume":"41","author":"Sassi","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"2024020319504235300_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319504235300_bib16","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319504235300_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","article-title":"Tartrate-resistant acid phosphatase isoform 5b as a marker for osteoclastic activity","volume":"47","author":"Janckila","year":"2001","journal-title":"Clin Chem"},{"key":"2024020319504235300_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00223-001-2122-7","article-title":"Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density","volume":"71","author":"Halleen","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2024020319504235300_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0009-8981(02)00026-8","article-title":"Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis","volume":"320","author":"Janckila","year":"2002","journal-title":"Clin Chim Acta"},{"key":"2024020319504235300_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1189\/jlb.0504287","article-title":"Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells","volume":"77","author":"Janckila","year":"2005","journal-title":"J Leukoc Biol"},{"key":"2024020319504235300_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cccn.2005.03.039","article-title":"Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a","volume":"359","author":"Chao","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2024020319504235300_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1309\/DGEA9BE2VE5VCFYH","article-title":"Tartrate-resistant acid phospahtase as an immunohistochemical marker for inflammatory macrophages","volume":"127","author":"Janckila","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2024020319504235300_bib23","doi-asserted-by":"crossref","first-page":"28370","DOI":"10.1074\/jbc.M502469200","article-title":"Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts","volume":"280","author":"Ljusberg","year":"2005","journal-title":"J Biol Chem"},{"key":"2024020319504235300_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cccn.2004.04.021","article-title":"Alternate immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin","volume":"347","author":"Janckila","year":"2004","journal-title":"Clin Chim Acta"},{"key":"2024020319504235300_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/jbmr.1999.14.3.464","article-title":"Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies","volume":"14","author":"Halleen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020319504235300_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/clinchem\/46.4.469","article-title":"Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum","volume":"46","author":"Nakanishi","year":"2000","journal-title":"Clin Chem"},{"key":"2024020319504235300_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/153685902760173917","article-title":"Characterization of four monoclonal antibodies to recombinant human tartrate-resistant acid phosphatase","volume":"21","author":"Miyazaki","year":"2002","journal-title":"Hybrid Hybridomics"},{"key":"2024020319504235300_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cca.2006.08.021","article-title":"Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b","volume":"376","author":"Ohashi","year":"2007","journal-title":"Clin Chim Acta"},{"key":"2024020319504235300_bib29","first-page":"2783","article-title":"Tartrate-resistant acid phosphatase 5b as a serum marker of bone metabolism in cancer patients","volume":"23","author":"Mose","year":"2003","journal-title":"Anticancer Res"},{"key":"2024020319504235300_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319504235300_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4065\/82.8.917","article-title":"The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis","volume":"82","author":"Tsai","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2024020319504235300_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1373\/clinchem.2003.029355","article-title":"Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Sch\u00f6nberg disease (Type II autosomal dominant osteopetrosis)","volume":"50","author":"Alatalo","year":"2004","journal-title":"Clin Chem"},{"key":"2024020319504235300_bib33","first-page":"943","article-title":"Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis","volume":"152","author":"Gravallese","year":"1998","journal-title":"Am J Pathol"},{"key":"2024020319504235300_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/002215540004800207","article-title":"Osteoclastic tartrate-resistant acid phosphatase (Acp5): Its localization to dendritic cells and diverse murine tissues","volume":"48","author":"Hayman","year":"2000","journal-title":"J Histochem Cytochem"},{"key":"2024020319504235300_bib35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00018-005-4550-4","article-title":"Differential expression of monomeric and proteolytically processed forms of tartrate-resistant acid phosphatase in rat tissues","volume":"62","author":"L\u00e5ng","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"2024020319504235300_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ard.62.3.196","article-title":"Tartrate-resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage","volume":"62","author":"Tsuboi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2024020319504235300_bib37","first-page":"63","article-title":"Synovial fluid acid phosphatase in seropositive and seronegative arthritides","volume":"8","author":"Lukkainen","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"2024020319504235300_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780330601","article-title":"The rheumatoid nodule","volume":"33","author":"Ziff","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2024020319504235300_bib39","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/1529-0131(199810)41:10<1783::AID-ART10>3.0.CO;2-W","article-title":"Pathogenic mechanisms in the rheumatoid nodule. Comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient","volume":"41","author":"Wikaningrum","year":"1998","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.080329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/8\/1287\/56570479\/5650230814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/8\/1287\/56570479\/5650230814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:50:51Z","timestamp":1710341451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/8\/1287-1295\/7599467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.080329","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,8,1]]},"published":{"date-parts":[[2008,8,1]]}}}